[Photo provided by JW Holdings]
Korea’s JW Holdings said on Thursday it won a patent in Japan for its technology to manufacture a multi-biomarker diagnostic kit that can detect pancreatic cancer during its early stages with a simple blood test.
JW Holdings shares on Thursday ended up 4.09 percent at 8,390 won ($7.84) in Seoul.
The technology is an innovative diagnostic platform that enables detection of pancreatic cancer by simultaneously using substances expressed during the disease’s early and late stage, the company said.
Until now, most pancreatic cancer diagnoses relied on testing CA19-9, a cancer-specific antigen that reacts primarily in end-stage patients, but the new kit is the first of its kind to test CFB antigens found during the early stages of pancreatic cancer.
JW Holdings is now better positioned to ensure its fast entry into the overseas in-vitro diagnostics market with the patent for the pancreatic cancer testing technology in Japan, said a company spokesman.
By Kim Hye-soon and Minu Kim
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]